Kim Son Nguyen, MD
Hematology/Oncology · Sunnyvale
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 14
- 2 carriers
- Office
- 1
Offices
1 location · Sutter Bay Medical Foundation · 3,783 clinicians in this group
Looking this up.
Hospitals listed: El Camino Health. That is not proof they admit you there this week.
Plans that list them
14 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Nguyen’s office at (408) 739-6000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
14 of 14 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Sutter Advantage +More (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A116347 · Current
Licensed to practise in California · since 2011 · expires 2026-12-31 · Harvard Medical School.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- El Camino HealthMountain View, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of El Camino Health, which runs 2 hospitalsPatients rate it 4 of 5 · 80% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.291, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.393, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0, Oct 2024 – Sep 2025
See every measure and the patient survey for El Camino Health
Behind the star rating — Deaths: 3 better, 5 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.291 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.393 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.96 (0.12 to 1.79) · 2,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.02 (0.76 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 167.38 (125.03 to 209.73) · 96 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 68 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 185 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 814 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13 · 842 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 361 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.6 · 4,633 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.34) · 11,474 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.1 to 0.45) · 11,626 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.14 (1.39 to 4.9) · 2,814 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2 (0.61 to 3.39) · 1,327 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.8 to 3.43) · 2,641 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.39 (4.18 to 14.6) · 1,287 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.57 (3.47 to 9.68) · 1,308 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.14 (0.71 to 3.57) · 827 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.6 (0.05 to 1.15) · 9,460 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.5 · 122 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.993 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.706 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.376 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.5 · 218 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.5 · 962 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 3.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -17 · 922 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 18.6 · 860 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.7 · 827 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.1 (4.5 to 8.2) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.4 (10.6 to 16.5) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.7 · 237 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (10 to 16.1) · 1,639 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.8 to 1.1) · 1,619 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,535 patients answered, 22% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 87% |
| "Always" quiet at night | 47% |
| "YES", patients would definitely recommend the hospital | 80% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
Original Medicare doctor bills
$3,161,265
Medicare paid this office $3,161,265 for 742 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Injection, pembrolizumab, 1 mg | 23 | $622,013 | None |
| Injection, daratumumab, 10 mg and hyaluronidase-fihj | 13 | $294,929 | None |
| Injection, immune globulin (privigen), intravenous, non-lyophilized (e.g., liquid), 500 mg | 16 | $174,880 | None |
| Long return visit (40+ min) | 138 | $70,018 | $164 |
| Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 12 | $63,653 | None |
See all 41 services
| Injection, pembrolizumab, 1 mg | 23 | $622,013 | None |
| Injection, daratumumab, 10 mg and hyaluronidase-fihj | 13 | $294,929 | None |
| Injection, immune globulin (privigen), intravenous, non-lyophilized (e.g., liquid), 500 mg | 16 | $174,880 | None |
| Long return visit (40+ min) | 138 | $70,018 | $164 |
| Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 12 | $63,653 | None |
| Injection, infliximab, excludes biosimilar, 10 mg | 12 | $39,521 | None |
| Administration of chemotherapy into vein, 1 hour or less | 113 | $38,533 | $141 |
| Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | 17 | $34,390 | $17 |
| Injection, denosumab, 1 mg | 19 | $33,331 | None |
| Return visit (30+ min) | 179 | $32,531 | $115 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 118 | $18,010 | $67 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 21 | $12,518 | None |
| New patient visit (60+ min) | 61 | $12,353 | $203 |
| Administration of additional new drug or substance into vein, 1 hour or less | 40 | $8,470 | $69 |
| Short return visit (20+ min) | 77 | $6,874 | $78 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 18 | $6,161 | $106 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 17 | $4,834 | $78 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 175 | $4,461 | $15 |
| New patient visit (45+ min) | 31 | $4,216 | $136 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 24 | $3,892 | $156 |
| Administration of additional new drug or substance into vein using push technique | 22 | $3,807 | $59 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 44 | $3,633 | $30 |
| Injection of additional new drug or substance into vein | 70 | $3,586 | $16 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 37 | $3,560 | $21 |
| Administration of chemotherapy into vein, each additional hour | 43 | $3,416 | $29 |
| Injection of drug or substance into vein | 52 | $2,043 | $36 |
| New patient visit (30+ min) | 20 | $1,950 | $97 |
| Injection of drug or substance under skin or into muscle | 58 | $1,886 | $14 |
| Injection, zoledronic acid, 1 mg | 64 | $1,745 | None |
| Injection, fosaprepitant, 1 mg | 36 | $1,353 | None |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 23 | $1,317 | $38 |
| Injection, carboplatin, 50 mg | 24 | $1,229 | None |
| Irrigation of implanted venous access drug delivery device | 16 | $1,132 | $28 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 18 | $549 | $20 |
| Injection, paclitaxel, 1 mg | 13 | $356 | None |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 12 | $294 | $23 |
| Infusion, normal saline solution, 250 cc | 164 | $157 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 44 | $107 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 48 | $106 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 42 | $45 | None |
| Unclassified drugs | 13 | $9 | None |
Who their Medicare patients are
742 Original Medicare patients in 2024. Average age 77 · Under 65 2% · 85 and older 19% · Women 60% · Also on Medicaid 10% · Health risk score 1.57. At or below the middle of the specialty; the typical hematology-oncology clinician is at 2.04.
Conditions among them: High blood pressure 68% · Cancer 40% · Chronic kidney disease 28% · Diabetes 24% · Coronary heart disease 24% · Atrial fibrillation 18% · Depression 17% · Heart failure 12% · COPD 11% · Stroke 8% · Dementia 7%.
The office billed $10,577,532, Medicare allowed $3,967,323 and paid $3,161,265; for 139,821 services of 142 kinds; $2,906,439 of it was for drugs given in the office and $254,826 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 742 | 139,821 | 77 | 1.57 | $10,577,532 | $3,161,265 |
| 2023 | 721 | 146,059 | 77 | 1.49 | $9,939,022 | $2,931,785 |
| 2022 | 730 | 129,330 | 77 | 1.51 | $8,550,320 | $2,720,103 |
| 2021 | 720 | 131,883 | 77 | 1.52 | $8,569,273 | $2,780,666 |
| 2020 | 683 | 158,744 | 76 | 1.73 | $8,690,820 | $2,824,818 |
| 2019 | 653 | 88,796 | 76 | 1.70 | $4,875,688 | $1,561,001 |
| 2018 | 583 | 54,414 | 75 | 1.71 | $3,436,554 | $1,108,954 |
| 2017 | 593 | 53,925 | 75 | 1.78 | $3,444,138 | $1,047,076 |
| 2016 | 395 | 29,233 | 75 | 1.80 | $1,573,885 | $430,614 |
| 2015 | 350 | 43,002 | 74 | 1.78 | $2,141,303 | $601,179 |
| 2014 | 117 | 7,817 | 75 | 1.50 | $378,666 | $106,828 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 44 services
| Injection, pembrolizumab, 1 mg | 25 | $788,308 | None |
| Injection, immune globulin (privigen), intravenous, non-lyophilized (e.g., liquid), 500 mg | 21 | $255,429 | None |
| Long return visit (40+ min) | 134 | $90,026 | $165 |
| Injection, infliximab, excludes biosimilar, 10 mg | 17 | $46,476 | None |
| Administration of chemotherapy into vein, 1 hour or less | 124 | $46,297 | $144 |
| Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | 17 | $41,997 | $23 |
| Injection, tocilizumab, 1 mg | 11 | $40,693 | None |
| Injection, denosumab, 1 mg | 14 | $34,243 | None |
| Injection, golimumab, 1 mg, for intravenous use | 11 | $29,049 | None |
| Return visit (30+ min) | 156 | $28,665 | $113 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 140 | $27,629 | $69 |
| Injection, pemetrexed, not otherwise specified, 10 mg | 11 | $19,822 | None |
| Leuprolide acetate (for depot suspension), 7.5 mg | 19 | $12,144 | None |
| New patient visit (60+ min) | 63 | $11,657 | $185 |
| Administration of additional new drug or substance into vein, 1 hour or less | 47 | $8,047 | $71 |
| Short return visit (20+ min) | 79 | $7,183 | $73 |
| New patient visit (45+ min) | 39 | $6,221 | $160 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 11 | $5,291 | $80 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 36 | $5,264 | $22 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 19 | $4,717 | $110 |
| Administration of chemotherapy into vein, each additional hour | 54 | $4,201 | $30 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 22 | $3,657 | $159 |
| Injection of additional new drug or substance into vein | 81 | $3,619 | $16 |
| Administration of additional new drug or substance into vein using push technique | 23 | $3,143 | $60 |
| Injection, zoledronic acid, 1 mg | 85 | $2,984 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 46 | $2,700 | $31 |
| Injection of drug or substance into vein | 56 | $2,668 | $37 |
| Instillation of anti-cancer drug into bladder | 13 | $2,008 | $74 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 27 | $1,754 | $35 |
| Injection of drug or substance under skin or into muscle | 48 | $1,741 | $14 |
| Injection, carboplatin, 50 mg | 30 | $966 | None |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 25 | $894 | $20 |
| Injection, fosaprepitant, 1 mg | 28 | $846 | None |
| Irrigation of implanted venous access drug delivery device | 22 | $696 | $28 |
| Injection, paclitaxel, 1 mg | 19 | $681 | None |
| Infusion into a vein for hydration, each additional hour | 26 | $649 | $14 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 11 | $477 | None |
| Infusion, normal saline solution, 250 cc | 193 | $192 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 59 | $127 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 61 | $121 | None |
| Infusion, normal saline solution , 1000 cc | 13 | $89 | None |
| Injection, methylprednisolone sodium succinate, up to 125 mg | 11 | $66 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 34 | $52 | None |
| Unclassified drugs | 15 | $12 | None |
2022: 40 services
| Injection, pembrolizumab, 1 mg | 23 | $666,201 | None |
| Injection, immune globulin (privigen), intravenous, non-lyophilized (e.g., liquid), 500 mg | 22 | $182,574 | None |
| Injection, pemetrexed, not otherwise specified, 10 mg | 13 | $115,619 | None |
| Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 13 | $109,735 | None |
| Long return visit (40+ min) | 144 | $89,888 | $167 |
| Injection, infliximab, excludes biosimilar, 10 mg | 21 | $60,545 | None |
| Administration of chemotherapy into vein, 1 hour or less | 119 | $47,576 | $151 |
| Injection, denosumab, 1 mg | 15 | $45,959 | None |
| Injection, golimumab, 1 mg, for intravenous use | 13 | $40,425 | None |
| Return visit (30+ min) | 199 | $33,364 | $113 |
| Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | 11 | $32,634 | $34 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 133 | $22,220 | $73 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 23 | $13,697 | None |
| New patient visit (60+ min) | 58 | $11,524 | $199 |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 13 | $6,647 | $1 |
| Short return visit (20+ min) | 69 | $6,033 | $80 |
| Administration of additional new drug or substance into vein, 1 hour or less | 33 | $5,676 | $73 |
| New patient visit (45+ min) | 37 | $4,916 | $133 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 41 | $4,330 | $32 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 31 | $3,884 | $21 |
| Injection of additional new drug or substance into vein | 67 | $3,761 | $17 |
| Bcg live intravesical instillation, 1 mg | 15 | $3,689 | None |
| Administration of chemotherapy into vein, each additional hour | 42 | $3,369 | $31 |
| Instillation of anti-cancer drug into bladder | 16 | $3,048 | $90 |
| Administration of additional new drug or substance into vein using push technique | 18 | $2,564 | $63 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 29 | $2,525 | $36 |
| Injection of drug or substance into vein | 49 | $2,377 | $39 |
| Injection of drug or substance under skin or into muscle | 49 | $2,316 | $14 |
| Injection, zoledronic acid, 1 mg | 70 | $1,992 | None |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 11 | $1,991 | $181 |
| Injection, fosaprepitant, 1 mg | 19 | $874 | None |
| Irrigation of implanted venous access drug delivery device | 14 | $707 | $29 |
| Injection, paclitaxel, 1 mg | 16 | $637 | None |
| Injection, carboplatin, 50 mg | 19 | $619 | None |
| Collection of blood sample from implanted device | 13 | $512 | $28 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 13 | $347 | $25 |
| Injection, methylprednisolone sodium succinate, up to 125 mg | 12 | $119 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 52 | $119 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 44 | $82 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 33 | $53 | None |
2021: 38 services
| Injection, pembrolizumab, 1 mg | 17 | $627,530 | None |
| Injection, immune globulin (privigen), intravenous, non-lyophilized (e.g., liquid), 500 mg | 18 | $170,444 | None |
| Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 16 | $162,355 | None |
| Return visit (30+ min) | 245 | $70,193 | $118 |
| Injection, denosumab, 1 mg | 23 | $69,480 | None |
| Injection, golimumab, 1 mg, for intravenous use | 13 | $58,493 | None |
| Injection, infliximab, excludes biosimilar, 10 mg | 17 | $56,549 | None |
| Administration of chemotherapy into vein, 1 hour or less | 111 | $45,781 | $161 |
| Long return visit (40+ min) | 68 | $26,654 | $169 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 109 | $23,957 | $79 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 31 | $18,078 | None |
| New patient visit (60+ min) | 58 | $11,608 | $200 |
| Short return visit (20+ min) | 102 | $10,682 | $82 |
| Administration of additional new drug or substance into vein, 1 hour or less | 42 | $7,297 | $78 |
| New patient visit (45+ min) | 46 | $6,862 | $149 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 12 | $6,502 | $89 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 24 | $5,254 | $96 |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 11 | $4,733 | $1 |
| Injection of additional new drug or substance into vein | 74 | $4,603 | $18 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 29 | $4,534 | $23 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 51 | $3,756 | $34 |
| Injection of drug or substance into vein | 65 | $3,180 | $44 |
| Instillation of anti-cancer drug into bladder | 11 | $3,154 | $79 |
| Injection of drug or substance under skin or into muscle | 65 | $2,827 | $14 |
| Injection, zoledronic acid, 1 mg | 64 | $2,654 | None |
| Administration of chemotherapy into vein, each additional hour | 35 | $2,545 | $33 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 38 | $2,466 | $34 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 13 | $2,407 | $185 |
| Administration of additional new drug or substance into vein using push technique | 15 | $2,070 | $67 |
| Injection, fosaprepitant, 1 mg | 28 | $1,738 | None |
| Irrigation of implanted venous access drug delivery device | 26 | $1,261 | $29 |
| Injection, paclitaxel, 1 mg | 17 | $1,035 | None |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 14 | $744 | None |
| Injection, carboplatin, 50 mg | 23 | $672 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 56 | $141 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 61 | $99 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 31 | $51 | None |
| Infusion, normal saline solution, 250 cc | 26 | $16 | None |
2020: 48 services
| Injection, pembrolizumab, 1 mg | 16 | $480,702 | None |
| Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 15 | $159,553 | None |
| Injection, immune globulin (privigen), intravenous, non-lyophilized (e.g., liquid), 500 mg | 16 | $144,181 | None |
| Injection, infliximab, excludes biosimilar, 10 mg | 17 | $104,317 | None |
| Injection, pegfilgrastim, 6 mg | 13 | $72,533 | None |
| Injection, denosumab, 1 mg | 18 | $69,586 | None |
| Injection, golimumab, 1 mg, for intravenous use | 11 | $58,696 | None |
| Return visit (30+ min) | 230 | $51,670 | $94 |
| Administration of chemotherapy into vein, 1 hour or less | 114 | $49,695 | $152 |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 13 | $44,124 | None |
| Unclassified drugs | 12 | $33,339 | None |
| Leuprolide acetate (for depot suspension), 7.5 mg | 30 | $28,567 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 103 | $23,009 | $75 |
| Long return visit (40+ min) | 48 | $9,349 | $135 |
| New patient visit (60+ min) | 49 | $9,300 | $190 |
| Injection, fosaprepitant, 1 mg | 25 | $8,058 | None |
| New patient visit (45+ min) | 52 | $7,950 | $153 |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 14 | $7,406 | $1 |
| Administration of additional new drug or substance into vein, 1 hour or less | 42 | $7,106 | $73 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 14 | $7,066 | $85 |
| Short return visit (20+ min) | 83 | $6,944 | $64 |
| Injection of additional new drug or substance into vein | 78 | $4,908 | $17 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 54 | $4,865 | $32 |
| Administration of chemotherapy into vein, each additional hour | 41 | $4,479 | $32 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 33 | $3,578 | $22 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 36 | $2,910 | $33 |
| Injection of drug or substance under skin or into muscle | 58 | $2,841 | $14 |
| Administration of additional new drug or substance into vein using push technique | 17 | $2,765 | $63 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 14 | $2,631 | $188 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 11 | $2,531 | $97 |
| Telephone medical discussion with physician, 21-30 minutes | 16 | $2,336 | $106 |
| Red blood cells, leukocytes reduced, each unit | 11 | $2,267 | $108 |
| Injection of drug or substance into vein | 50 | $2,211 | $39 |
| Injection, zoledronic acid, 1 mg | 50 | $1,931 | None |
| Telephone medical discussion with physician, 11-20 minutes | 25 | $1,752 | $67 |
| Injection, paclitaxel, 1 mg | 19 | $1,351 | None |
| Irrigation of implanted venous access drug delivery device | 20 | $1,268 | $29 |
| Injection, carboplatin, 50 mg | 27 | $1,216 | None |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 13 | $904 | None |
| Transfusion of blood or blood products | 12 | $687 | $38 |
| Collection of blood sample from implanted device | 11 | $525 | $28 |
| Application of on-body injector for under skin injection | 11 | $430 | $20 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 17 | $408 | $24 |
| Injection, dexamethasone sodium phosphate, 1 mg | 57 | $150 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 57 | $116 | None |
| Injection, methylprednisolone sodium succinate, up to 125 mg | 12 | $114 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 38 | $52 | None |
| Infusion, normal saline solution, 250 cc | 24 | $13 | None |
2019: 36 services
| Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 18 | $146,772 | None |
| Injection, rituximab, 10 mg | 12 | $105,719 | None |
| Injection, infliximab, excludes biosimilar, 10 mg | 19 | $97,084 | None |
| Injection, immune globulin (privigen), intravenous, non-lyophilized (e.g., liquid), 500 mg | 18 | $81,924 | None |
| Return visit (30+ min) | 273 | $66,696 | $96 |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 11 | $38,697 | None |
| Administration of chemotherapy into vein, 1 hour or less | 99 | $31,965 | $149 |
| Injection, denosumab, 1 mg | 13 | $28,958 | None |
| Long return visit (40+ min) | 69 | $15,309 | $137 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 92 | $15,253 | $75 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 19 | $13,879 | None |
| New patient visit (60+ min) | 48 | $9,153 | $191 |
| New patient visit (45+ min) | 49 | $6,618 | $135 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 26 | $6,440 | $95 |
| Administration of additional new drug or substance into vein, 1 hour or less | 34 | $4,397 | $72 |
| Injection, fosaprepitant, 1 mg | 16 | $4,005 | None |
| Administration of chemotherapy into vein, each additional hour | 43 | $3,872 | $31 |
| Injection of additional new drug or substance into vein | 68 | $3,522 | $17 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 18 | $3,501 | $184 |
| Short return visit (20+ min) | 46 | $3,309 | $61 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 28 | $2,210 | $22 |
| Injection of drug or substance into vein | 44 | $2,153 | $40 |
| Injection of drug or substance under skin or into muscle | 49 | $1,905 | $16 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 36 | $1,903 | $32 |
| Injection, zoledronic acid, 1 mg | 45 | $1,871 | None |
| Administration of additional new drug or substance into vein using push technique | 12 | $1,548 | $62 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 22 | $1,286 | $32 |
| Irrigation of implanted venous access drug delivery device | 19 | $1,108 | $28 |
| Injection, paclitaxel, 1 mg | 21 | $961 | None |
| Injection, carboplatin, 50 mg | 25 | $785 | None |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 20 | $465 | $23 |
| Injection, methylprednisolone sodium succinate, up to 125 mg | 11 | $141 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 49 | $108 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 50 | $104 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 36 | $45 | None |
| Infusion, normal saline solution, 250 cc | 38 | $21 | None |
2018: 32 services
| Injection, pembrolizumab, 1 mg | 14 | $191,034 | None |
| Injection, pegfilgrastim, 6 mg | 11 | $64,600 | None |
| Return visit (30+ min) | 258 | $60,336 | $94 |
| Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 13 | $59,736 | None |
| Injection, infliximab, excludes biosimilar, 10 mg | 15 | $48,684 | None |
| Injection, immune globulin (privigen), intravenous, non-lyophilized (e.g., liquid), 500 mg | 11 | $43,852 | None |
| Administration of chemotherapy into vein, 1 hour or less | 80 | $19,256 | $149 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 20 | $11,847 | None |
| New patient visit (60+ min) | 63 | $11,484 | $182 |
| New patient visit (45+ min) | 66 | $9,426 | $143 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 57 | $8,059 | $75 |
| Long return visit (40+ min) | 34 | $5,458 | $133 |
| Short return visit (20+ min) | 55 | $3,799 | $61 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 17 | $3,411 | $83 |
| Administration of additional new drug or substance into vein, 1 hour or less | 22 | $2,487 | $71 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 12 | $2,353 | $65 |
| Injection of additional new drug or substance into vein | 47 | $2,344 | $18 |
| Biopsy and aspiration of bone marrow sample for diagnosis | 12 | $2,055 | $171 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 25 | $1,852 | $21 |
| Injection of drug or substance under skin or into muscle | 48 | $1,809 | $19 |
| Administration of chemotherapy into vein, each additional hour | 23 | $1,297 | $32 |
| Administration of additional new drug or substance into vein using push technique | 11 | $1,283 | $61 |
| Injection of drug or substance into vein | 24 | $1,107 | $44 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 23 | $914 | $32 |
| Injection, zoledronic acid, 1 mg | 21 | $829 | None |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 25 | $693 | $22 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 11 | $544 | $32 |
| Irrigation of implanted venous access drug delivery device | 11 | $528 | $28 |
| Injection, carboplatin, 50 mg | 14 | $482 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 41 | $65 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 31 | $41 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 20 | $19 | None |
2017: 37 services
| Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 15 | $96,905 | None |
| Injection, pegfilgrastim, 6 mg | 15 | $69,311 | None |
| Injection, infliximab, excludes biosimilar, 10 mg | 19 | $65,969 | None |
| Return visit (30+ min) | 232 | $55,276 | $92 |
| Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | 15 | $39,556 | None |
| Injection, denosumab, 1 mg | 14 | $37,832 | None |
| Administration of chemotherapy into vein, 1 hour or less | 87 | $22,266 | $144 |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 12 | $17,469 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 68 | $10,866 | $71 |
| New patient visit (60+ min) | 55 | $10,176 | $185 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 16 | $8,499 | None |
| Long return visit (40+ min) | 51 | $7,912 | $122 |
| New patient visit (45+ min) | 50 | $7,298 | $146 |
| Injection of drug or substance into vein | 40 | $5,426 | $57 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 22 | $5,182 | $65 |
| Short return visit (20+ min) | 62 | $4,729 | $67 |
| Injection of additional new drug or substance into vein | 55 | $3,164 | $23 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 12 | $2,846 | $77 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 18 | $2,807 | $122 |
| Injection of drug or substance under skin or into muscle | 57 | $2,530 | $25 |
| Administration of additional new drug or substance into vein, 1 hour or less | 26 | $2,490 | $67 |
| Injection, zoledronic acid, 1 mg | 37 | $1,680 | None |
| Bcg (intravesical) per instillation | 11 | $1,658 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 26 | $1,482 | $19 |
| Instillation of anti-cancer drug into bladder | 11 | $1,384 | $81 |
| Administration of chemotherapy into vein, each additional hour | 25 | $1,167 | $28 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 26 | $1,156 | $33 |
| Infusion into a vein for hydration, 31-60 minutes | 12 | $1,078 | $60 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 14 | $684 | $31 |
| Infusion into a vein for hydration, each additional hour | 14 | $647 | $15 |
| Transfusion of blood or blood products | 13 | $631 | $37 |
| Irrigation of implanted venous access drug delivery device | 12 | $443 | $26 |
| Injection, carboplatin, 50 mg | 13 | $354 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 48 | $79 | None |
| Infusion, normal saline solution, 250 cc | 30 | $46 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 37 | $42 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 24 | $19 | None |
2016: 23 services
| Return visit (30+ min) | 188 | $39,937 | $92 |
| Administration of chemotherapy into vein, 1 hour or less | 49 | $11,543 | $137 |
| Long return visit (40+ min) | 40 | $9,313 | $126 |
| New patient visit (60+ min) | 49 | $8,923 | $182 |
| New patient visit (45+ min) | 45 | $6,337 | $141 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 19 | $4,372 | $64 |
| Short return visit (20+ min) | 30 | $2,034 | $60 |
| Injection of additional new drug or substance into vein | 32 | $2,032 | $23 |
| Administration of additional new drug or substance into vein, 1 hour or less | 16 | $1,855 | $64 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 23 | $1,831 | $70 |
| Injection of drug or substance under skin or into muscle | 37 | $1,523 | $25 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 12 | $1,426 | $119 |
| Injection of drug or substance into vein | 14 | $1,279 | $58 |
| Administration of chemotherapy into vein, each additional hour | 15 | $1,049 | $28 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 14 | $702 | $18 |
| Irrigation of implanted venous access drug delivery device | 17 | $674 | $26 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 15 | $674 | $31 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 12 | $455 | $33 |
| Injection, carboplatin, 50 mg | 12 | $387 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 31 | $56 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 24 | $52 | None |
| Infusion, normal saline solution, 250 cc | 14 | $43 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 15 | $12 | None |
2015: 27 services
| Injection, rituximab, 100 mg | 15 | $103,435 | None |
| Return visit (30+ min) | 138 | $38,507 | $101 |
| Administration of chemotherapy into vein, 1 hour or less | 83 | $23,539 | $144 |
| Injection, tbo-filgrastim, 5 micrograms | 17 | $7,297 | None |
| Leuprolide acetate (for depot suspension), 7.5 mg | 11 | $6,908 | None |
| New patient visit (60+ min) | 39 | $6,835 | $175 |
| Injection of additional new drug or substance into vein | 69 | $5,475 | $24 |
| New patient visit (45+ min) | 35 | $5,117 | $146 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 12 | $4,226 | $80 |
| Administration of additional new drug or substance into vein, 1 hour or less | 34 | $4,066 | $67 |
| Long return visit (40+ min) | 29 | $4,019 | $134 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 33 | $4,018 | $74 |
| Unclassified drugs | 11 | $4,012 | None |
| Injection of drug or substance under skin or into muscle | 44 | $2,503 | $26 |
| Administration of chemotherapy into vein, each additional hour | 33 | $2,076 | $29 |
| Administration of additional new drug or substance into vein using push technique | 13 | $2,046 | $66 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 14 | $1,479 | $19 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 25 | $1,426 | $32 |
| Short return visit (20+ min) | 17 | $1,425 | $71 |
| Injection, carboplatin, 50 mg | 20 | $980 | None |
| Injection, paclitaxel, 1 mg | 16 | $822 | None |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 11 | $443 | $34 |
| Irrigation of implanted venous access drug delivery device | 13 | $350 | $27 |
| Injection, dexamethasone sodium phosphate, 1 mg | 57 | $136 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 48 | $64 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 34 | $30 | None |
| Infusion, normal saline solution, 250 cc | 15 | $18 | None |
2014: 8 services
| New patient visit (60+ min) | 36 | $6,782 | $188 |
| Return visit (30+ min) | 21 | $5,504 | $100 |
| Administration of chemotherapy into vein, 1 hour or less | 18 | $3,287 | $137 |
| Long return visit (40+ min) | 14 | $1,867 | $133 |
| New patient visit (45+ min) | 12 | $1,821 | $152 |
| Injection of drug or substance under skin or into muscle | 17 | $672 | $25 |
| Injection of additional new drug or substance into vein | 15 | $605 | $22 |
| Injection, dexamethasone sodium phosphate, 1 mg | 12 | $15 | None |
Medicaid work
$83 in 2021
Medicaid paid $83 for 16 billed services this clinician did in 2021, up to 14 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 16 | $83 |
| 2021 | 16 | 1 | 14 | $83 |
| 2018 | 12 | 1 | 12 | $433 |
See the largest Medicaid services in earlier years
2018
| Return visit (30+ min) | 12 | $433 |
Drugs they prescribed that Part D paid
$4,131,087
Pharmacies billed $4,131,087 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 1% of their Part D prescriptions (12 of 850) in 2024. At or below the middle of the specialty; the typical hematology-oncology clinician is at 5%.
548 generic and fewer than 11 brand-name prescriptions · $4,131,087 in drug cost · 26 antibiotic prescriptions.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Xtandi | 66 | $969,515 | $14,690 |
| Imbruvica | 31 | $822,898 | $26,545 |
| Jakafi | 23 | $480,693 | $20,900 |
| Tagrisso | 29 | $453,096 | $15,624 |
| Erleada | 22 | $323,709 | $14,714 |
See all 22 drugs
| Xtandi | 66 | $969,515 | $14,690 |
| Imbruvica | 31 | $822,898 | $26,545 |
| Jakafi | 23 | $480,693 | $20,900 |
| Tagrisso | 29 | $453,096 | $15,624 |
| Erleada | 22 | $323,709 | $14,714 |
| Venclexta | 19 | $141,788 | $7,463 |
| Lenalidomide | 13 | $128,330 | $9,872 |
| Eliquis | 43 | $30,030 | $698 |
| Cyclosporine | 12 | $3,753 | $313 |
| Hydroxyurea | 73 | $2,592 | $36 |
| Abiraterone Acetate | 15 | $2,112 | $141 |
| Anastrozole | 62 | $1,570 | $25 |
| Erlotinib | 12 | $1,026 | $86 |
| Dexamethasone | 46 | $719 | $16 |
| Acyclovir | 23 | $533 | $23 |
| Tamoxifen Citrate | 21 | $481 | $23 |
| Ondansetron | 44 | $479 | $11 |
| Prochlorperazine Maleate | 51 | $440 | $9 |
| Prednisone | 26 | $177 | $7 |
| Gabapentin | 12 | $138 | $11 |
| Sulfamethoxazole-Trimethoprim | 21 | $115 | $5 |
| Pantoprazole | 13 | $53 | $4 |
Year by year
| 2024 | 850 | 156 | 1% (12) | None | $4,131,087 |
| 2023 | 728 | 140 | 2% (17) | None | $3,437,103 |
| 2022 | 768 | 131 | 2% (13) | None | $3,260,218 |
| 2021 | 833 | 125 | 2% (18) | 28% | $3,044,267 |
| 2020 | 733 | 112 | 3% (22) | 31% | $2,594,119 |
| 2019 | 688 | 129 | 4% (28) | 30% | $2,127,089 |
| 2018 | 688 | 119 | 5% (31) | 34% | $2,108,100 |
| 2017 | 639 | 115 | 4% (23) | 22% | $882,760 |
| 2016 | 421 | 76 | 9% (36) | None | $624,743 |
| 2015 | 282 | 55 | 7% (21) | 15% | $248,817 |
| 2014 | 75 | 19 | None | 21% | $19,136 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 16 drugs
| Imbruvica | 33 | $949,170 | $28,763 |
| Tagrisso | 22 | $368,863 | $16,766 |
| Lenalidomide | 19 | $282,104 | $14,848 |
| Venclexta | 17 | $146,066 | $8,592 |
| Eliquis | 41 | $34,960 | $853 |
| Xarelto | 18 | $26,508 | $1,473 |
| Abiraterone Acetate | 14 | $15,233 | $1,088 |
| Hydroxyurea | 78 | $4,046 | $52 |
| Anastrozole | 53 | $2,220 | $42 |
| Dexamethasone | 47 | $821 | $17 |
| Tamoxifen Citrate | 18 | $817 | $45 |
| Acyclovir | 31 | $720 | $23 |
| Prochlorperazine Maleate | 46 | $591 | $13 |
| Ondansetron | 34 | $402 | $12 |
| Prednisone | 25 | $275 | $11 |
| Levothyroxine | 14 | $169 | $12 |
2022: 19 drugs
| Imbruvica | 37 | $579,794 | $15,670 |
| Revlimid | 34 | $574,660 | $16,902 |
| Tagrisso | 25 | $390,001 | $15,600 |
| Xtandi | 13 | $174,416 | $13,417 |
| Mekinist | 12 | $170,837 | $14,236 |
| Tafinlar | 12 | $157,349 | $13,112 |
| Alecensa | 12 | $102,801 | $8,567 |
| Eliquis | 36 | $38,161 | $1,060 |
| Xarelto | 16 | $19,604 | $1,225 |
| Erlotinib | 13 | $12,583 | $968 |
| Abiraterone Acetate | 22 | $12,106 | $550 |
| Hydroxyurea | 102 | $4,488 | $44 |
| Anastrozole | 52 | $1,936 | $37 |
| Acyclovir | 26 | $772 | $30 |
| Prochlorperazine Maleate | 50 | $740 | $15 |
| Ondansetron | 27 | $697 | $26 |
| Dexamethasone | 26 | $606 | $23 |
| Levothyroxine | 22 | $394 | $18 |
| Prednisone | 35 | $293 | $8 |
2021: 21 drugs
| Imbruvica | 66 | $976,082 | $14,789 |
| Revlimid | 48 | $782,596 | $16,304 |
| Pomalyst | 14 | $278,450 | $19,889 |
| Lenvima | 11 | $223,656 | $20,332 |
| Xtandi | 17 | $211,516 | $12,442 |
| Tagrisso | 12 | $201,820 | $16,818 |
| Alecensa | 12 | $95,621 | $7,968 |
| Abiraterone Acetate | 28 | $34,976 | $1,249 |
| Erlotinib | 12 | $21,840 | $1,820 |
| Xarelto | 16 | $19,724 | $1,233 |
| Imatinib Mesylate | 14 | $11,249 | $803 |
| Hydroxyurea | 124 | $5,272 | $43 |
| Anastrozole | 58 | $2,260 | $39 |
| Acyclovir | 37 | $821 | $22 |
| Tamoxifen Citrate | 17 | $745 | $44 |
| Dexamethasone | 37 | $673 | $18 |
| Prochlorperazine Maleate | 52 | $661 | $13 |
| Ondansetron | 22 | $406 | $18 |
| Alendronate | 15 | $315 | $21 |
| Levothyroxine | 20 | $300 | $15 |
| Prednisone | 39 | $258 | $7 |
2020: 18 drugs
| Revlimid | 56 | $948,748 | $16,942 |
| Imbruvica | 40 | $563,398 | $14,085 |
| Tagrisso | 18 | $289,677 | $16,093 |
| Pomalyst | 12 | $216,902 | $18,075 |
| Alecensa | 12 | $104,241 | $8,687 |
| Abiraterone Acetate | 24 | $33,532 | $1,397 |
| Erlotinib | 12 | $32,385 | $2,699 |
| Xarelto | 20 | $21,850 | $1,093 |
| Imatinib Mesylate | 12 | $7,212 | $601 |
| Eliquis | 13 | $5,910 | $455 |
| Hydroxyurea | 109 | $5,575 | $51 |
| Anastrozole | 68 | $2,776 | $41 |
| Dexamethasone | 39 | $1,023 | $26 |
| Acyclovir | 33 | $648 | $20 |
| Prochlorperazine Maleate | 44 | $589 | $13 |
| Alendronate | 20 | $400 | $20 |
| Ondansetron | 20 | $338 | $17 |
| Prednisone | 32 | $203 | $6 |
2019: 16 drugs
| Revlimid | 48 | $671,667 | $13,993 |
| Imbruvica | 34 | $431,056 | $12,678 |
| Tagrisso | 17 | $260,072 | $15,298 |
| Tarceva | 15 | $129,531 | $8,635 |
| Gilotrif | 12 | $105,272 | $8,773 |
| Alecensa | 11 | $87,633 | $7,967 |
| Xarelto | 12 | $8,998 | $750 |
| Hydroxyurea | 93 | $4,759 | $51 |
| Anastrozole | 79 | $2,892 | $37 |
| Dexamethasone | 35 | $909 | $26 |
| Acyclovir | 37 | $660 | $18 |
| Prochlorperazine Maleate | 48 | $469 | $10 |
| Ondansetron | 26 | $411 | $16 |
| Alendronate | 25 | $397 | $16 |
| Prednisone | 21 | $165 | $8 |
| Sulfamethoxazole-Trimethoprim | 14 | $93 | $7 |
2018: 15 drugs
| Revlimid | 49 | $747,759 | $15,260 |
| Imbruvica | 26 | $300,764 | $11,568 |
| Tagrisso | 12 | $174,230 | $14,519 |
| Gilotrif | 21 | $173,166 | $8,246 |
| Tarceva | 14 | $127,787 | $9,128 |
| Lonsurf | 14 | $114,813 | $8,201 |
| Xarelto | 41 | $23,906 | $583 |
| Hydroxyurea | 112 | $5,961 | $53 |
| Anastrozole | 68 | $2,031 | $30 |
| Dexamethasone | 21 | $353 | $17 |
| Ondansetron | 27 | $308 | $11 |
| Alendronate | 21 | $218 | $10 |
| Prochlorperazine Maleate | 37 | $217 | $6 |
| Acyclovir | 11 | $148 | $13 |
| Lorazepam | 19 | $73 | $4 |
2017: 15 drugs
| Revlimid | 29 | $386,950 | $13,343 |
| Tarceva | 28 | $224,389 | $8,014 |
| Imatinib Mesylate | 11 | $84,726 | $7,702 |
| Xarelto | 32 | $16,420 | $513 |
| Eliquis | 11 | $5,090 | $463 |
| Hydroxyurea | 79 | $3,343 | $42 |
| Anastrozole | 60 | $1,615 | $27 |
| Anagrelide | 16 | $1,387 | $87 |
| Prochlorperazine Maleate | 43 | $307 | $7 |
| Ondansetron | 26 | $270 | $10 |
| Dexamethasone | 18 | $231 | $13 |
| Alendronate | 20 | $224 | $11 |
| Lorazepam | 54 | $181 | $3 |
| Letrozole | 13 | $144 | $11 |
| Prednisone | 16 | $135 | $8 |
2016: 13 drugs
| Revlimid | 11 | $167,015 | $15,183 |
| Tarceva | 20 | $147,053 | $7,353 |
| Zytiga | 15 | $129,012 | $8,601 |
| Xarelto | 22 | $10,481 | $476 |
| Hydroxyurea | 35 | $1,235 | $35 |
| Anastrozole | 31 | $946 | $31 |
| Letrozole | 12 | $307 | $26 |
| Prednisone | 24 | $261 | $11 |
| Ondansetron | 14 | $221 | $16 |
| Omeprazole | 12 | $167 | $14 |
| Lorazepam | 33 | $152 | $5 |
| Dexamethasone | 18 | $127 | $7 |
| Prochlorperazine Maleate | 13 | $77 | $6 |
2015: 8 drugs
| Hydroxyurea | 39 | $1,332 | $34 |
| Tamoxifen Citrate | 14 | $497 | $35 |
| Ondansetron | 24 | $294 | $12 |
| Anastrozole | 16 | $277 | $17 |
| Lorazepam | 41 | $154 | $4 |
| Prochlorperazine Maleate | 28 | $145 | $5 |
| Prednisone | 13 | $125 | $10 |
| Dexamethasone | 11 | $60 | $5 |
2014: 1 drug
| Amlodipine Besylate | 11 | $29 | $3 |
Money from drug and device companies
$425 in 2025
| 2025 | 7 | 10 | None | $425 |
| 2022 | 1 | 1 | None | $12 |
| 2021 | 1 | 1 | None | $13 |
| 2019 | 3 | 3 | None | $67 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| AstraZeneca Pharmaceuticals LP | Imfinzi | $239 | 3 payments
|
| Kite Pharma | Yescarta | $57 | 2 payments
|
| Recordati Rare Diseases Inc. | Enjaymo | $33 | 1 payment
|
| Abbvie | Venclexta | $29 | 1 payment
|
| Astellas Pharma US | Padcev | $27 | 1 payment
|
| Array Biopharma | Lorbrena | $25 | 1 payment
|
See all 10 published payments
| Kite Pharma | Meals · 2025-12-01 | Yescarta | $29 |
| AstraZeneca Pharmaceuticals LP | Education · 2025-11-13 | Imfinzi | $35 |
| Recordati Rare Diseases Inc. | Meals · 2025-09-11 | Enjaymo | $33 |
| Abbvie | Meals · 2025-09-10 | Venclexta | $29 |
| Astellas Pharma US | Meals · 2025-08-20 | Padcev | $27 |
| AstraZeneca Pharmaceuticals LP | Education · 2025-07-29 | Imfinzi | $68 |
| Array Biopharma | Meals · 2025-07-09 | Lorbrena | $25 |
| Kite Pharma | Meals · 2025-05-22 | Yescarta | $28 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-05-08 | None | $135 |
| Pfizer | Education · 2025-04-28 | Ibrance | $16 |
See earlier years (2022, 2021, 2019)
2022: $12
| PharmaEssentia USA | Besremi | $12 | 1 payment
|
2021: $13
| Pfizer | Inlyta | $13 | 1 payment
|
2019: $67
| Amgen | None | $30 | 1 payment
|
| Relypsa | Veltassa | $24 | 1 payment
|
| Seattle Genetics | Adcetris | $12 | 1 payment
|
Professional record
- NPI
- 1831357029
- Licence
- CA A116347California A116347: Current · expires 2026-12-31
- Trained
- Harvard Medical School, 2007
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Medical oncology (207RX0202X); Internal medicine (207R00000X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2008-05-25
- NPI last updated
- 2024-04-15
- NPI record certified
- 2024-04-15
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 301 Old San Francisco Rd, Sunnyvale, CA, 94086